GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (LTS:0RKL) » Definitions » E10

Xvivo Perfusion AB (LTS:0RKL) E10 : kr0.91 (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Xvivo Perfusion AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Xvivo Perfusion AB's adjusted earnings per share data for the three months ended in Dec. 2024 was kr1.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr0.91 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Xvivo Perfusion AB's average E10 Growth Rate was 133.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2025-03-05), Xvivo Perfusion AB's current stock price is kr413.16102. Xvivo Perfusion AB's E10 for the quarter that ended in Dec. 2024 was kr0.91. Xvivo Perfusion AB's Shiller PE Ratio of today is 454.02.

During the past 13 years, the highest Shiller PE Ratio of Xvivo Perfusion AB was 1814.29. The lowest was 467.58. And the median was 1053.85.


Xvivo Perfusion AB E10 Historical Data

The historical data trend for Xvivo Perfusion AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB E10 Chart

Xvivo Perfusion AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.14 0.39 0.91

Xvivo Perfusion AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.46 0.54 0.80 0.91

Competitive Comparison of Xvivo Perfusion AB's E10

For the Medical Devices subindustry, Xvivo Perfusion AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Shiller PE Ratio falls into.



Xvivo Perfusion AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=1.15/132.9872*132.9872
=1.150

Current CPI (Dec. 2024) = 132.9872.

Xvivo Perfusion AB Quarterly Data

per share eps CPI Adj_EPS
201503 -0.002 99.950 -0.003
201506 0.050 99.995 0.066
201509 0.060 100.228 0.080
201512 0.130 100.276 0.172
201603 0.050 100.751 0.066
201606 0.070 101.019 0.092
201609 -0.020 101.138 -0.026
201612 -0.020 102.022 -0.026
201703 -0.002 102.022 -0.003
201706 0.040 102.752 0.052
201709 -0.010 103.279 -0.013
201712 0.210 103.793 0.269
201803 0.150 103.962 0.192
201806 0.150 104.875 0.190
201809 0.004 105.679 0.005
201812 0.180 105.912 0.226
201903 -0.010 105.886 -0.013
201906 0.080 106.742 0.100
201909 0.180 107.214 0.223
201912 -0.080 107.766 -0.099
202003 0.250 106.563 0.312
202006 -0.600 107.498 -0.742
202009 -0.510 107.635 -0.630
202012 -0.700 108.296 -0.860
202103 0.200 108.360 0.245
202106 -0.310 108.928 -0.378
202109 -0.040 110.338 -0.048
202112 0.420 112.486 0.497
202203 0.160 114.825 0.185
202206 0.260 118.384 0.292
202209 0.180 122.296 0.196
202212 0.020 126.365 0.021
202303 0.480 127.042 0.502
202306 0.230 129.407 0.236
202309 0.080 130.224 0.082
202312 2.170 131.912 2.188
202403 0.720 132.205 0.724
202406 0.860 132.716 0.862
202409 2.710 132.304 2.724
202412 1.150 132.987 1.150

Add all the adjusted EPS together and divide 10 will get our e10.


Xvivo Perfusion AB  (LTS:0RKL) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Xvivo Perfusion AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=413.16102/0.91
=454.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Xvivo Perfusion AB was 1814.29. The lowest was 467.58. And the median was 1053.85.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Xvivo Perfusion AB E10 Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB Business Description

Traded in Other Exchanges
Address
Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB Headlines

No Headlines